{"id":"civacir-10","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Back pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Civacir contains pooled human immunoglobulin with high titers of antibodies against hepatitis C virus. It is administered intravenously to HCV-positive patients undergoing liver transplantation to neutralize circulating HCV virions and reduce the risk of graft reinfection. The antibodies bind to viral particles and prevent them from infecting the newly transplanted liver.","oneSentence":"Civacir is a hepatitis C immunoglobulin (HCV-IG) that provides passive immunity by supplying antibodies against hepatitis C virus to prevent reinfection in transplant recipients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:10.145Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis C virus reinfection in HCV-positive patients undergoing orthotopic liver transplantation"}]},"trialDetails":[{"nctId":"NCT01804829","phase":"PHASE3","title":"Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.","status":"COMPLETED","sponsor":"Biotest Pharmaceuticals Corporation","startDate":"2013-06","conditions":"Hepatitis C Infection, Viruses, Hepatocellular Carcinoma","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Civacir®","Hepatitis C Immune Globulin Intravenous (Human)","human polyclonal immune globulin (IgG)","HCIg"],"phase":"phase_3","status":"active","brandName":"Civacir® 10%","genericName":"Civacir® 10%","companyName":"Biotest Pharmaceuticals Corporation","companyId":"biotest-pharmaceuticals-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"Civacir is a hepatitis C immunoglobulin (HCV-IG) that provides passive immunity by supplying antibodies against hepatitis C virus to prevent reinfection in transplant recipients. Used for Prevention of hepatitis C virus reinfection in HCV-positive patients undergoing orthotopic liver transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}